title: Subtypes in monosymptomatic nocturnal enuresis. II.
abstract: Lasting cure rates in monosymptomatic nocturnal enuresis (MNE), using the alarm, imipramine or desmopressin, have been quoted as 43%, 17% and 22%, respectively. The low cure rates in addition to the number of different treatments indicate insufficient knowledge of MNE. Only research on arginine vasopressin (AVP) levels and nocturnal enuresis is unique in attempting to find a group within the MNE population that could benefit from substitution therapy with desmopressin. AVP levels are restored or amplified during desmopressin treatment. However, low nocturnal AVP production with high nocturnal urine output may be indicative of a disturbance in circadian rhythm. Pre-clinical data suggest a role for melatonin in the regulation of endogenous AVP and in the regulation of the sleep/wake cycle.
authors.affiliation: Pediatric Renal Center, University Children's Hospital, Utrecht, The Netherlands.
authors.forename: J D
authors.initials: JD
authors.lastname: van Gool
authors.forename: E
authors.initials: E
authors.lastname: Nieuwenhuis
authors.forename: I O
authors.initials: IO
authors.lastname: ten Doeschate
authors.forename: T P
authors.initials: TP
authors.lastname: Messer
authors.forename: T P
authors.initials: TP
authors.lastname: de Jong
mesh_terms: D001127:Arginine Vasopressin / Q000097:blood; D002648:Child; D002675:Child, Preschool; D002940:Circadian Rhythm / Q000187:drug effects; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage; D004775:Enuresis / Q000145:classification* / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D016896:Treatment Outcome; D014563:Urodynamics / Q000187:drug effects
chemical_list: D001127:Arginine Vasopressin; D003894:Deamino Arginine Vasopressin